Table 2. Predictive factors of overall liver transplantation-free survival in HCC patients treated with TACE.
| Factors | Patients with better survival (n = 72) | Patients with worse survival (n = 126) | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Gender (male) | 50 (86.1) | 101 (80.2) | 1.39 (0.91–2.15) | 0.132 | ||
| Age, yr (≥ 55) | 60.1 (10.4) | 57.8 (10.3) | 0.69 (0.48–0.98) | 0.040 | 0.81 (0.55–1.19) | 0.285 |
| Diabetes mellitus | 10 (13.9) | 25 (19.8) | 1.19 (0.77–1.85) | 0.436 | ||
| HBeAg positivity | 33 (46.5) | 57 (45.6) | 0.88 (0.62–1.25) | 0.460 | ||
| Cirrhosis | 71 (98.6) | 117 (92.9) | 0.50 (0.25–0.99)a | 0.046a | ||
| Child-Pugh class (B/C) | 5.4 (0.9) | 5.8 (1.5) | 1.80 (1.16–2.80)a | 0.009a | ||
| Platelet, ×109/L (< 100) | 126.7 (78.8) | 136.7 (78.4) | 0.94 (0.66–1.36) | 0.755 | ||
| Creatinine, mg/dL | 1.1 (1.2) | 1.0 (0.6) | 0.89 (0.56–1.40) | 0.602 | ||
| Albumin, g/L | 3.9 (0.6) | 3.6 (0.6) | 0.60 (0.46–0.80)a | 0.000a | 0.73 (0.51–1.05) | 0.091 |
| Bilirubin, mg/dL | 1.0 (0.7) | 1.2 (1.0) | 1.40 (1.16–1.69)a | 0.000a | 0.93 (0.69–1.27) | 0.665 |
| ALT, U/L | 44.3 (35.4) | 56.4 (66.1) | 1.00 (1.00–1.00) | 0.423 | ||
| INR | 1.1 (0.2) | 1.2 (0.2) | 4.21 (1.89–9.40)a | 0.000a | 3.52 (0.98–12.67) | 0.054 |
| AFP (> 400 ng/mL) | 603.5 (1,889.5) | 4,204.8 (12,800.1) | 2.06 (1.42–2.98)a | 0.000a | 1.38 (0.91–2.07) | 0.126 |
| HBV DNA, log10 IU/mL | 3.6 (2.2) | 4.5 (2.0) | 1.13 (1.04–1.23)a | 0.004a | 1.01 (0.92–1.11) | 0.786 |
| Tumor number (≥ 2) | 1.7 (0.8) | 2.6 (1.7) | 1.32 (0.93–1.88) | 0.126 | ||
| Tumor size (≥ 2 cm) | 3.3 (2.3) | 5.5 (3.4) | 3.86 (2.02–7.38)a | 0.000a | 3.04 (1.51–6.11)a | 0.002a |
| Macrovascular invasion | 4 (5.6) | 338 (30.2) | 4.05 (2.73–6.02)a | 0.000a | 3.57 (2.32–5.48)a | 0.000a |
| miRNA-21 (≥ 2.5) | 4.9 (8.8) | 6.7 (11.2) | 1.28 (0.90–1.81) | 0.174 | ||
| miRNA-26a (≥ 1.5) | 6.5 (36.4) | 3.1 (3.6) | 1.23 (0.86–1.75) | 0.250 | ||
| miRNA-29a (< 0.4) | 0.38 (0.30) | 0.35 (0.31) | 1.20 (0.84–1.71) | 0.328 | ||
| miRNA-panel (all 3 met or not) | 1.30 (0.91–1.87) | 0.155 | ||||
Values are presented as number (%) or HR (95% CI).
HCC = hepatocellular carcinoma, TACE = transarterial chemoembolization, HR = hazard ratio, CI = confidence interval, HBeAg = hepatitis B e antigen, ALT = alanine aminotransferase, INR = international normalized ratio, AFP = alpha-fetoprotein, HBV = hepatitis B virus, miRNA = microRNA.
aP < 0.05.